Cynata (ASX: CYP) appoints Dr Kilian Kelly as CEO & MD, welcomes Dr David Atkins to Board - Kalkine Media

Highlights

• Dr Kilian Kelly has been appointed to the position of Cynata’s Chief Executive Officer and Managing Director
• Dr Geoff Brooke, Chairman of the ASX-listed entity, commented that Dr Kelly's appointment reflects the "exciting growth and maturation” of the company
• Additionally, Dr David Atkins, managing partner of BioScience Managers, has been welcomed to the company’s Board of Directors

Cynata Therapeutics (ASX: CYP) -- a publicly listed stem cell and regenerative medicine company – has announced the appointment of Dr Kilian Kelly as Chief Executive Officer and Managing Director with effect from 1 July 2023. Dr Kelly has been CYP's Chief Operating Officer since May 2019. The appointment follows the retirement of Dr Ross Macdonald, the current CEO and MD of Cynata.

Additionally, Cynata Therapeutics has welcomed Dr David Atkins -- the Managing Partner of BioScience Managers, a major shareholder of CYP -- onto its Board of Directors. Dr Stewart Washer is stepping down from his position as non-executive director.

Source: Company update

Cynata Therapeutics’ Chairman Dr Geoff Brooke remarked that Dr Kilian Kelly's elevation comes at a crucial time and shows "exciting growth and maturation" of CYP.

Dr Kelly has shown extraordinary capability in swiftly progressing the company's products from laboratory to clinical trials, most notably the development of Cynata’s CYP-001 (company’s lead Cymerus™ product for aGvHD), added Dr Brooke.

About Dr David Atkins

Dr Atkins has rich experience of over 25 years in leading life science, healthcare, and related businesses, with past stints at Johnson & Johnson and Danaher. It is mentioned that he holds commercial expertise of working in the North American, EMEA, Asian and Latin American markets.

Notably, Dr Atkins has also founded or served in leadership roles at three startup companies operating in gene therapy, cancer diagnostics and related domains.

Dr David Atkins, who has been inducted into the Board, notes that the iPSC-derived MSC therapeutic products development company Cynata has numerous active and near-term development and partnering opportunities, thanks to the company’s robust clinical pipeline.